Marker Therapeutics (NASDAQ:MRKR – Free Report) had its price objective hoisted by LADENBURG THALM/SH SH from $11.00 to $19.00 in a research report report published on Monday, Benzinga reports. The brokerage currently has a buy rating on the stock.
Marker Therapeutics Price Performance
Shares of NASDAQ:MRKR opened at $4.01 on Monday. Marker Therapeutics has a one year low of $2.40 and a one year high of $6.16. The firm has a fifty day moving average price of $3.15 and a two-hundred day moving average price of $3.98.
Marker Therapeutics (NASDAQ:MRKR – Get Free Report) last posted its earnings results on Wednesday, August 14th. The company reported ($0.25) EPS for the quarter. Marker Therapeutics had a negative return on equity of 78.91% and a negative net margin of 278.27%. The business had revenue of $1.17 million for the quarter. Sell-side analysts forecast that Marker Therapeutics will post -1.43 EPS for the current fiscal year.
Institutional Investors Weigh In On Marker Therapeutics
Marker Therapeutics Company Profile
Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.
Featured Stories
- Five stocks we like better than Marker Therapeutics
- Airline Stocks – Top Airline Stocks to Buy Now
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- The How and Why of Investing in Gold Stocks
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- 5 discounted opportunities for dividend growth investors
- Tesla Stock: Buy the Dips, Sell the Rips
Receive News & Ratings for Marker Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marker Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.